News
Equity Residential (NYSE:EQR) is one of the most undervalued stocks. On June 5, Stifel maintained a Buy rating on EQR with a ...
Vistagen Therapeutics, Inc. (NASDAQ:VTGN) is among the best growth stocks to invest in for the next 5 years. Analysts at ...
Financial services provider Stifel (NYSE:SF) announced on Thursday an increase in its May-end client assets, and estimated ...
Oracle (ORCL) shares rose more than 6% on Monday after CEO Safra Catz touted a "strong start" to fiscal 2026 and investment ...
According to Benzinga Pro, Stifel Financial's peer group average for short interest as a percentage of float is 3.25%, which ...
The $1.5 billion settlement in 2003 and 2004 addressed a scandal over analysts issuing positive research to help Citigroup, ...
Stifel, Nicolaus & Company, Inc., has been ordered by a Finra arbitration panel to pay a family of four investors more than $132 million for breach of fiduciary and negligence tied to risky ...
Stifel co-president Nesi to retire, join board as Institutional Group revenue soars under his tenure
One of the financial services company's top investment bankers is retiring after 16 years, but he'll still have a role with ...
Two employees of Stifel Financial Corp. in London departed the US investment bank after a probe into alleged inappropriate relationships with a cleaner.. Allegations about improper relationships ...
Equity Residential (NYSE:EQR) is one of the most undervalued stocks. On June 5, Stifel maintained a Buy rating on EQR with a price target of $69.01. The analysts highlighted that Q2 fundamentals ...
Analysts at Stifel reiterated their Buy rating on Vistagen Therapeutics, Inc. (NASDAQ:VTGN) with an unchanged price target of $12.00 post the company’s fiscal 2025 announcement.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results